Free Trial

Royalty Pharma Q2 2024 Earnings Report

Royalty Pharma logo
$24.92 +0.64 (+2.64%)
(As of 12/20/2024 05:51 PM ET)

Royalty Pharma EPS Results

Actual EPS
$0.96
Consensus EPS
$0.95
Beat/Miss
Beat by +$0.01
One Year Ago EPS
$0.85

Royalty Pharma Revenue Results

Actual Revenue
$537.00 million
Expected Revenue
$600.83 million
Beat/Miss
Missed by -$63.83 million
YoY Revenue Growth
N/A

Royalty Pharma Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Royalty Pharma Earnings Headlines

This Indicator called BOTH NVDA rallies
Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…
See More Royalty Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Royalty Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Royalty Pharma and other key companies, straight to your email.

About Royalty Pharma

Royalty Pharma (NASDAQ:RPRX) operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

View Royalty Pharma Profile

More Earnings Resources from MarketBeat

Upcoming Earnings